<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362919">
  <stage>Registered</stage>
  <submitdate>20/08/2012</submitdate>
  <approvaldate>27/08/2012</approvaldate>
  <actrnumber>ACTRN12612000910808</actrnumber>
  <trial_identification>
    <studytitle>Sevoflurane aggravate minimal hepatic encephalopath in cirrhosis patients</studytitle>
    <scientifictitle>Sevoflurane aggravate minimal hepatic encephalopathy in cirrhosis patients compared to propofol</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>minimal hepatic encephalopathy</healthcondition>
    <healthcondition>general anesthesia</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2-3% sevoflurane (to maintain bispectral index values 40-60) inhaled during the operation (2-4h, vary on a case by case basis depending on the operation).</interventions>
    <comparator>administration of propofol through  target controlled infusion at 4-8mg/kg/h (to maintain bispectral index values 40-60) during the operation</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Minimal hepatic encephalopathy detected by 20% increase in the number connection test (NCT) score</outcome>
      <timepoint>2 day and 7 day after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Minimal hepatic encephalopathy detected by 20% increase in the line tracing test (LTT) score</outcome>
      <timepoint>2 day and 7 day after surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients  who had evidence of cirrhosis by clinical, biochemical, and/or histological criteria with ASA class 1 or 2 scheduled for elective surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients with active bleeding or with overt encephalopathy, patients with known allergy to sedative, known significant respiratory disease, active neurological impairment, advanced or decompensated liver disease (CP score &gt;9, Child-Pugh class C), ongoing alcohol or drug abuse, psychiatric illness, monocular vision, mental impairment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Natural Science Foundation of China</primarysponsorname>
    <primarysponsoraddress>83 Shuangqing Road, Beijing 100085</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Natural Science Foundation of China</fundingname>
      <fundingaddress>83 Shuangqing Road, Beijing 100085</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Eastern Hepatobiliary Surgery Hospital</sponsorname>
      <sponsoraddress>225 Changhai Road, Shanghai 200438</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with minimal hepatic encephalopathy (MHE) have impaired motor function and visuomotor cordination, which make them unsafe in their life. Evaluation of MHE stage in surgery patients with hepatic cirrhosis is an important problem for the inhalation of anesthetics. We have previously observed that sevoflurane induced increased MHE scores in non-hepatic surgery patients with cirrhosis, suggesting that inhaled anesthetics can. In this study, we try to demonstrate the effect of sevoflurane on MHE in cirrhosis patients by a randomized controlled clinical observation.  This study would be helpful for the perioperative anesthetic application in patients with cirrhosis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Xue-rong Miao</name>
      <address>225 Changhai Road, Shanghai 200438, China.</address>
      <phone>+86 13636551152</phone>
      <fax />
      <email>miaoxuerong@gmail.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Xue-rong Miao</name>
      <address>225 Changhai Road, Shanghai 200438, China.</address>
      <phone>+86 13636551152</phone>
      <fax />
      <email>miaoxuerong@gmail.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>